Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
National Health and Medical Research Council, Australia Doris Duke Charitable Foundation Cancer Council Tasmania Duke Institute on Care at the End of Life, USA Flinders Medical Research Institute Small Research Grants Scheme, Australia |
---|---|
Information provided by: | National Institute on Aging (NIA) |
ClinicalTrials.gov Identifier: | NCT00327873 |
The main goal of this study is to establish the effectiveness of palliative oxygen in the context within which it is usually provided--relief of the sensation of breathlessness and improvement in quality of life for people with maximally-treated life-limiting illness.
Condition | Intervention | Phase |
---|---|---|
Dyspnea |
Other: Oxygen Other: Medical Air |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Active Control, Parallel Assignment, Efficacy Study |
Official Title: | A Multi-Center Randomized Double-Blind Controlled Trial of Oxygen Versus Medical Air for the Relief of Breathlessness in Patients With Intractable Dyspnea and PaO2>55mmHg |
Estimated Enrollment: | 240 |
Study Start Date: | May 2005 |
Estimated Study Completion Date: | March 2008 |
Estimated Primary Completion Date: | March 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
A: Experimental
Oxygen
|
Other: Oxygen
2L/min for 15 hours or greater per day via concentrator and nasal cannulae for 7 days
|
B: Active Comparator
Medical Air
|
Other: Medical Air
2L/min for 15 hours or greater per day via concentrator and nasal cannulae for 7 days
|
When further medical management will not relieve intractable breathlessness, palliative oxygen is often prescribed regardless of whether the person meets the common oxygen funding criteria of severely low blood oxygen levels. The results of this study will inform best practice in the care of people with advanced life-limiting illness and intractable breathlessness, aid in the development of rational funding guidelines, and answer an international debate on the role of palliative oxygen.
This study is a definitive international multi-center randomized double-blind controlled trial of oxygen versus medical air for the relief of breathlessness in participants with intractable dyspnea and PaO2>55mmHg (a measure of blood oxygen levels). Specific aims include demonstration of the effectiveness of oxygen versus medical air in relieving breathlessness in the palliative setting (Specific Aim 1) and improving QOL (Specific Aim 2). Additionally, we will seek to establish which patients derive the greatest benefit (Specific Aim 3), the risks of therapy (Specific Aim 4), and the costs of therapy (Specific Aim 5). The primary hypothesis is that oxygen therapy is superior to air in relieving the sensation of breathlessness for patients with intractable dyspnea due to life-limiting illness in the setting of PaO2>55mmHg.
All participants are enrolled as outpatients. The "eligibility visit" occurs about 5-7 days before starting the study and will include review of the consent form, a short interview, physical exam, and blood tests. The visit can occur in the home or clinic. The blood tests include regular venipuncture and also an arterial blood gas, if these studies have not been done in the preceding month. The "randomization visit" occurs 2 days before the study starts (Day -2) and includes a short interview and quality of life (QOL) questionnaire; this visit is usually done in the home but can also occur in the clinic. The oxygen or air concentrators are delivered to the home on Day 0 by a trained person from the oxygen company. On the same day there is also a brief home visit from the study nurse that includes a short interview and QOL questionnaire. The participant uses the oxygen or medical air gas each of 7 days (Days 0-6) for at least 15 hours each day. While using the oxygen/air the participant fills out a short diary form in the morning and evening, within 30 minutes of waking up or retiring. The diary focuses on the breathlessness, how the participant is feeling, and potential side effects of the gas. The study nurse conducts a "check-in" telephone call on Day 3 to make sure the participant is doing OK. On the last day (Day 6) the nurse visits the home to conduct a brief interview with a short QOL questionnaire. The oxygen company will pick up the concentrator, usually on Day 7.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Amy Abernethy, MD | 919-668-0647 | amy.abernethy@duke.edu |
Contact: Linda Hood, RN, MSN, AOCN | 919-681-2598 | hood0004@mc.duke.edu |
United States, North Carolina | |
Duke University Department of Medicine, Division of Medical Oncology | Recruiting |
Durham, North Carolina, United States, 27710 | |
Contact: Amy Abernethy, MD 919-668-0647 amy.abernethy@duke.edu | |
Contact: Linda Hood, RN, MSN, AOCN 919-681-2598 hood0004@mc.duke.edu | |
Principal Investigator: Amy P. Abernethy, MD | |
Sub-Investigator: Elizabeth C. Clipp, RN,BSN,MSN,PhD | |
Sub-Investigator: Kevin A. Schulman, MD, MBA | |
Sub-Investigator: James A. Tulsky, MD | |
Sub-Investigator: Kevin P. Weinfurt, PhD | |
Sub-Investigator: Kevin J. Anstrom, PhD | |
Australia, New South Wales | |
Sydney Area Health Service, Sydney Cancer Centre | Recruiting |
Sydney, New South Wales, Australia, 2050 | |
Contact: Katherine Clark, MBBS,FRACP,FAChPM,MA 61 02 95157755 katherine.clark@email.cs.nsw.gov.au | |
Principal Investigator: Katherine Clark, MBBS,FRACP,FAChPM,MA | |
Sub-Investigator: Iven Young, MBBS,PhD,FRACP | |
Sub-Investigator: Jan Maree Davis, BMed,FAChPM,FRACP | |
Australia, South Australia | |
Flinders University, Southern Adelaide Palliative Services | Recruiting |
Adelaide, South Australia, Australia, 5041 | |
Contact: Belinda Fazekas (+61 8) 8275 1057 Belinda.fazekas@rgh.sa.gov.au | |
Principal Investigator: David Currow, BMed,FRACP,MPH | |
Sub-Investigator: Peter A. Frith, MBBS,FRACP | |
Sub-Investigator: Belinda S. Fazekas, BN | |
Sub-Investigator: Alan Crockett, MPH, PhD | |
Australia, Tasmania | |
Statewide Palliative Care Service | Recruiting |
Launceston, Tasmania, Australia, 7250 | |
Contact: David Woods, MBBS, FAChPM (+61 3) 6336-5544 David.woods@dhhs.tas.gov.au | |
Principal Investigator: David Woods, MBBS, FAChPM | |
Australia, Victoria | |
Austin Health | Recruiting |
Melbourne, Victoria, Australia, 3084 | |
Contact: Christine McDonald, MBBS, PhD (+61 3) 9496-5760 christine.mcdonald@austin.org.au | |
Principal Investigator: Christine McDonald, MBBS, PhD | |
United Kingdom | |
St Nicholas Hospice | Recruiting |
Cambridge, United Kingdom, IP33 2QY UK | |
Contact: Sarah Booth, MBBS, FFARCSI +44 (01223) 586703 sara.booth@addenbrookes.nhs.uk | |
Principal Investigator: Sarah Booth, MBBS,FFARCSI | |
Nottingham University | Recruiting |
Nottingham, United Kingdom, NG5 1PB | |
Contact: Andrew Wilcock, MBChB,DM,FRCP +44 115 9691169 ext 46450 Andrew.Wilcock@nottingham.ac.uk | |
Principal Investigator: Andrew Wilcock, MBChB,DM,FRCP |
Principal Investigator: | Amy Abernethy, MD | Duke University |
Principal Investigator: | David Curow, BMed,FRACP,MPH | Flinders University, Australia |
Responsible Party: | Duke Cancer Care Research Program, Duke University Medical Center ( Amy Abernethy, MD, Assistant Professor of Medicine ) |
Study ID Numbers: | AG0064 |
Study First Received: | May 18, 2006 |
Last Updated: | March 19, 2008 |
ClinicalTrials.gov Identifier: | NCT00327873 |
Health Authority: | United States: Federal Government |
breathlessness shortness of breath end-of-life care hospice |
Signs and Symptoms Respiratory Tract Diseases Respiration Disorders Signs and Symptoms, Respiratory Dyspnea |